This fall, CMS will start sharing monthly utilization reports with Part D plans on how their enrollees are using the Medicare GLP-1 Bridge program. The agency said in an Aug. 5 memo that the reports will be organized at both…
GLP-1s
Eli Lilly and Co. extended its advantage over Novo Nordisk in the GLP-1 market during the second quarter, even as Novo’s oral Wegovy notched a strong early launch. Lilly reported Aug. 5 second-quarter revenue of $22.97 billion, up 48% year…
An international panel of experts has published a systematic review and consensus guidelines on the use of incretin-based medications in women’s reproductive health, offering hospitals and clinicians recommendations for counseling patients before, during and after pregnancy, according to research published…
CVS Health has revamped its direct-to-consumer weight management program to expand access to GLP-1 medications. The company lowered the cost of MinuteClinic online weight loss visits to $29, down from $49 at launch in June, with no recurring membership or…
As employers scale back coverage for GLP-1 weight-loss drugs, major retailers and pharmacy chains are expanding direct-to-consumer prescription programs to capture patients shifting to cash-pay options. Walmart, Costco, Amazon and CVS are investing in programs that combine GLP-1 prescriptions with…
Advertisement
Eli Lilly has built a formal expanded access program for retatrutide, its experimental obesity drug, following weeks of physician inquiries about securing the same early access previously granted to a single patient. “For a limited number of patients who meet…
GLP-1 therapies may allow clinicians to tailor obesity treatment to patients’ individual cardiometabolic needs rather than focusing on weight loss alone, according to a July 27 analysis published in the journal Diabetes, Obesity, and Metabolism. Researchers from the Perelman School…
The U.S. Department of Veterans Affairs is launching a clinical trial to evaluate whether semaglutide, a GLP-1 receptor agonist used to treat diabetes, can treat alcohol use disorder among veterans, according to a July 30 news release. The trial comes…
Cigna pulled back GLP-1 weight-loss coverage for its own employees July 1. Now it says its clients have been doing the same. On a July 30 earnings call, Cigna President and CEO Brian Evanko said Evernorth Health Services has seen…
Demand for GLP-1 weight loss drugs and other temperature-sensitive therapies is driving shipping and logistics companies to expand their healthcare operations, according to a July 25 CNBC report. UPS, FedEx, DHL and C.H. Robinson are investing in temperature-controlled storage, cold-chain…